Korean J Gastroenterol.  2023 Jun;81(6):276-278. 10.4166/kjg.2023.049.

Gastrointestinal Stromal Tumor of Small Intestine

• Song HY
• Seo GS
• Jo HG

• KMID: 2543449
• DOI: http://doi.org/10.4166/kjg.2023.049

Figure

• 

  Fig. 1 (A) Abdominal and pelvic computed tomography shows about 2.5 cm sized well defined solid mass with subtle central low attenuation at left upper quadrant, abutting jejunum loop (yellow arrow). (B) Capsule endoscopy shows active bleeding in the jejunum at 15 minutes. (C) Enteroscopy shows a subepithelial lesion covered by normal mucosa with central ulceration and blood clots in the jejunum.

• 

  Fig. 2 Histology images. (A) Image shows GIST composed of spindle cells (hematoxylin-eosin, original magnifications x40). Immunohistochemical staining images show positive for (B) KIT and (C) DOG1 (original magnifications x40).

Reference

1. Rubin BP, Heinrich MC, Corless CL. 2007; Gastrointestinal stromal tumour. Lancet. 369:1731–1741. Erratum in: Lancet 2007; 370:388. DOI: 10.1016/s0140-6736(07)60780-6. PMID: 23623056.

2. Tran T, Davila JA, El-Serag HB. 2005; The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 100:162–168. DOI: 10.1111/j.1572-0241.2005.40709.x. PMID: 15654796.

3. Nilsson B, Bümming P, Meis-Kindblom JM, et al. 2005; Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer. 103:821–829. DOI: 10.1002/cncr.20862. PMID: 15648083.

4. Tzen CY, Wang JH, Huang YJ, et al. 2007; Incidence of gastrointestinal stromal tumor: a retrospective study based on immunohistochemical and mutational analyses. Dig Dis Sci. 52:792–797. DOI: 10.1007/s10620-006-9480-y. PMID: 17253141. PMCID: PMC7087581.

5. Miettinen M, Lasota J. 2001; Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 438:1–12. DOI: 10.1007/s004280000338. PMID: 11213830.

6. Akahoshi K, Oya M, Koga T, Shiratsuchi Y. 2018; Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol. 24:2806–2817. DOI: 10.3748/wjg.v24.i26.2806. PMID: 30018476. PMCID: PMC6048423.

7. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. 2016; The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 19:3–14. DOI: 10.1007/s10120-015-0526-8. PMID: 26276366. PMCID: PMC4688306.

8. West RB, Corless CL, Chen X, et al. 2004; The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 165:107–113. DOI: 10.1016/s0002-9440(10)63279-8. PMID: 15215166. PMCID: PMC1618538.

9. Hamed H, Wahab MA, Elmahdy Y, El-Wahab RMA, El-Magd EA. 2023; Gastrointestinal stromal tumors of the small intestine: the challenge of diagnosis and the outcome of management. World J Surg Oncol. 21:85. DOI: 10.1186/s12957-023-02968-0. PMID: 36894972. PMCID: PMC9996990.

10. Koo DH, Ryu MH, Kim KM, et al. 2016; Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor. Cancer Res Treat. 48:1155–1166. DOI: 10.4143/crt.2016.187. PMID: 27384163. PMCID: PMC5080813.

11. Joensuu H, Eriksson M, Sundby Hall K, et al. 2012; One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 307:1265–1272. DOI: 10.3410/f.716497827.791902835. PMID: 22453568.

12. Verweij J, Casali PG, Zalcberg J, et al. 2004; Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 364:1127–1134. DOI: 10.1016/s0140-6736(04)17098-0. PMID: 15451219.